Close Menu

NEW YORK – Diagnostic test developers targeting oncology applications were the apple of investors' eyes in 2019, driven in part by advances in technology and a more favorable investment environment, according to diagnostic industry analysts.

In 2019, they noted, investors spent heavily on companies developing tests for cancer therapy selection, therapy monitoring, and screening for early-stage disease.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.